|
RESprotect
Name
Address/P.O. Box
Postal Code/City
State
Contact Person
Telephone
Fax
Email Address
Internet Website
Number of Employees
Founded (year)
Type of Laboratory
Areas of Activity
External Collaborations
Request for
Further Collaborations
|
RESprotect GmbH
Fiedlerstr. 34
D-01307 Dresden
Saxony
Prof. Dr. Rudolf Fahrig
+49-351-4503200
+49-351-4503210
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.resprotect.com
10
2000
S1
Cancer chemotherapy;
Chemotherapy of infectious diseases
WITEGA/Berlin; Nycomed/Linz,
Austria; ERCOM/Budapest,
Hungary; Clinics Chemnitz;
University Leipzig; University
Munich; Technical University
Munich;University Vienna/
Austria; Avantogen/San Diego,
USA.
Partnering: RESprotect is looking for the appropriate partner to develop its key project RP101 in Europe, South America and Asia,
and its follow-on compounds worlwide.
|
- RESprotect - Prevention of Chemoresistance - Overview
RESprotect GmbH is a privately owned biotechnology company located in Dresden Germany. RESprotect is focusing on the inhibition of chemoresistance and the enhancement of chemosensitivity. In contrast to the well known efforts to circumvent or decrease existing chemoresistance, this basic approach is unrivalled. RESprotect was founded in 2000. The founder is geneticist and came from the Fraunhofer-Institute for Toxicology in Hannover. At present clinical studies on RP101 are performed with pancreas cancer patients. The next generation of more efficient compounds is being explored, and a general broadening of the clinical indications is in process. RESprotect is in the position to enter a segment of the huge market of anticancer cytostatics. Use patents exist and an extension of the patent portfolio by substance patents was achieved in 2006. New chemical entities have been identified and introduced to the development pipeline.
- Combating Chemoresistance - Chemogenomics joins the battleground
In cancer model systems, chemoresistance is often mediated by a single gene, and, therefore, may in theory be inhibited by any drug that targets the product of that targets that gene. These drugs possess potency and specificity for only one of the several reasons for chemoresistance. For this reason, the chemogenomics approach focuses on small molecules, causing favorable phenotypic changes, and inhibiting or preventing the induction of chemoresistance. The drugs have to counteract the over-expression of apoptosis-antagonizing genes and to enhance the immune responses. By influencing not only one but a number of different validated targets a new class of effective anti-cancer drugs will be developed. These compounds have to be administered in addition to standard chemotherapy. RP101 is the first drug that shows these effects in tumor cells in cultured tumor cells, in animals and in patients.
- RP101 improves the efficasy of chemotherapy treatment in pancreatic carcinoma cells and patients
In pre-clinical studies, RP101 has shown strong antitumor effects due to inhibition of chemoresistance and the enforcement of apoptotic response upon drug treatment. RP101
|
